Extract: "The principle of AOD9604, already proven in animal studies, is to mimic the natural fat reducing properties of human growth hormone without producing any effects on blood sugar control or growth. In the 10 mg dose group, the overall weight loss was 1.0 kg compared to 0.4 kg in the placebo group, and in the 20 older volunteers the weight loss was 0.8 kg compared to a weight gain of 0.1 kg in the placebo group".
" MBP believes that the drug has a favourable side effect profile when compared with existing drugs on the market which mostly act on the brain to affect appetite and have many side effects.
Sofar, clinical trials have been very encouraging". See "F&Q", web site: http://www.metabolic.com.au/ ______________________________ Gominer: " this one works on the metabolism which is a fat storage incubator, not on the hunger factor." ________________________________ Investor update, date 21/5/03 http://stocknessmonster.com/news-item?S=MBP&E=ASX&N=204500
Extract: "Success for prototype AOD GM seed. Metabolic has been working with SemBioSys Genetics Inc. of Canada to assess the feasibility of producing a genetically modified (GM) food containing AOD9604.
It is proposed that the GM food will be primarily used as a veterinary application to reduce back fat in pigs and obesity in companion animals.
A feasibility study conducted by Australian company, BresaGen Ltd, has successfully concluded that AOD9604 can be manufactured using recombinant processes (genetically engineered bacteria).
This well-established technology is currently usedin the manufacture of many biopharmaceuticals, such as insulin and growth hormone.
The feasibility study confirmed that AOD9604 can be made efficiently in bacteria. BresaGen has delivered a sample to Metabolic and our laboratory tests show it is identical to synthetically produced AOD9604, both chemically and in terms of biological activity".